Category: Urovant

Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

Pivotal Phase 3 EMPOWUR study met both co-primary endpoints, with significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively), and a favorable safety and tolerability profile   Efficacy observed at week 2 and maintained through week 12 in co-primary endpoints Data showed once-daily 75 mg dose has…

Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

IRVINE, Calif. & BASEL, Switzerland, March 27, 2019–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological…

Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively) Vibegron met all seven key secondary endpoints, including a clinically meaningful reduction in daily urgency episodes versus placebo (p=0.002) Vibegron achieved rapid onset at two weeks in both co-primary endpoints and…

Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019

BASEL, Switzerland & IRVINE, Calif. — (BUSINESS WIRE) — Jan. 15, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019. The event will feature presentations by clinical experts in the field of…

Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder

More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target Top-line efficacy and safety data from Phase 3 trial expected by the end of March 2019 BASEL, Switzerland and IRVINE, Calif., November 8, 2018/Business Wire – Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for…

Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology

BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 1, 2018– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced the publication of positive results from the international Phase 2b study of vibegron, an investigational oral beta-3 adrenergic agonist being studied for adults with symptoms of overactive bladder (OAB). The study, which demonstrated…